We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 816

C.D. Cal. Dismisses Infusion Pump Complaint
  • Reed Smith LLP
  • USA
  • April 27 2016

The plaintiff in Frere v. Medtronic, Inc., 2016 WL 1533524 (C.D. Cal. April 6, 2014), was an 80 year-old woman who had an infusion pump implanted to


Innovator Drug510k Medical Device Impossibility Preemption and the Meaning of “A Fortiori”
  • Reed Smith LLP
  • USA
  • April 22 2016

According to Black's Law Dictionary, "a fortiori" is legal Latin meaning: By even greater force of logic; even more so it follows . We've been


TPPs Fail to Put Their Money Where Their (Litigation) Mouth Is and Lose
  • Reed Smith LLP
  • USA
  • April 20 2016

In third party payor litigation over prescription medical products, we have often marveled at the causation arguments that plaintiffs have offered


Gutsy Gatekeeping: Plaintiffs’ Experts Excluded in Lipitor MDL
  • Reed Smith LLP
  • USA
  • April 19 2016

This week, as Drug and Device Law Jews, we are preparing for Passover, which, like most Jewish holidays, begins with a multi-generational dinner at


Summary Judgment for Defendants in FCA Action: No Admissible Evidence of False Claims
  • Reed Smith LLP
  • USA
  • April 15 2016

How much is "enough?" Will we have enough money to retire someday? Did the Drug and Device Law College Sophomore study enough for her computer


Learning Something New - Limits To Human Tissue Liability
  • Reed Smith LLP
  • USA
  • April 13 2016

Every now and then even Bexis comes across a decision involving legal propositions he’d never heard of before. Such was the human tissue case


FDA Biosimilars Guidance Not Conducive To Preemption
  • Reed Smith LLP
  • USA
  • April 11 2016

The FDA recently released draft guidance concerning the labeling of biosimilar products (analogous in the biologic context to generic drugs).It's


So Long Zoloft MDL
  • Reed Smith LLP
  • USA
  • April 7 2016

The Zoloft MDL has finally collapsed. We started to see the writing on the wall in June 2014, when the MDL judge ruled that none of the plaintiffs'


Bauman Personal Jurisdiction In-House Counsel Checklist
  • Reed Smith LLP
  • USA
  • April 4 2016

The revolution in personal jurisdiction touched off by Daimler AG v. Bauman, 134 S. Ct. 746 (2014) ("Bauman"), is in full swing.The favorable results


Comment K Case by Case - Falling Out of Favor?
  • Reed Smith LLP
  • USA
  • April 1 2016

When we examined Restatement (Second) of Torts 402A, comment k (1965), in our 2011 research post “Comment K, Some of the Way,” we remarked about